Donovan Joanne M.

CMO Donovan executes multi-day liquidation totaling ~$2.1M, reducing holdings while stock trades below recent highs amid unprofitable operations.

Joanne M. Donovan, the company's Chief Medical Officer, executed a three-transaction liquidation over two days that removed approximately $2.1 million in value from her holdings. The pattern—two sales bracketing an unusual share acquisition—is noteworthy: the middle transaction (a five-fold increase in holdings at a sharply lower price) suggests either a vesting event or compensatory arrangement that she immediately monetized through a larger subsequent sale. Combined, these moves liquidated the bulk of her position. The timing occurs as the stock trades below its recent highs and the company is unprofitable with widening losses, creating a backdrop where an executive's decision to convert equity into cash warrants investor attention. The scale and speed of this reduction suggests conviction about near-term capital needs or reduced confidence in near-term upside, though the magnitude relative to her role does not suggest crisis-level concern.

CMO Donovan sold 28,662 shares (74.9% of holdings) at $32.31; stock now at $33.33 near 52-week high.

CMO Joanne M. Donovan sold 28,662 shares for $926,095.02 on 2026-04-01, reducing her position from 38,259 shares to 9,597 shares—a 74.9% reduction of her pre-transaction holdings. The sale occurred at $32.31, and the current price is $33.33, placing the stock at its 52-week high (+0.0% from the upper bound of $11.42–$33.33). The company reported a net loss of $40,666,000.00 over its most recent full fiscal year. Notably, this is the fourth sale by Donovan at EWTX within a span of days (three consecutive sales on 2026-03-27 and 2026-03-31), suggesting a coordinated disposition of a large position rather than opportunistic trading. Across her prior cross-ticker trading history, Donovan's 4 prior open-market sells showed a well-timed rate of 100.00% with an average 90-day return of -43.2%, indicating her sales have historically preceded stock declines. However, the same-ticker history at EWTX shows only one measurable outcome (2025-01-28 sale: 90d return -43.2%), while the three most recent EWTX sales lack measurable 90d returns yet. This substantial insider reduction of stake near a 52-week high, combined with an unprofitable company and her demonstrated pattern of well-timed sells cross-ticker, warrants investor attention despite the short measurement window for the current transaction cluster.

CMO Donovan Joanne M. sold 21,338 shares of EWTX at $32.12 (near 52-week high of $31.94); stock unprofitable with $-40.7M net income.

Donovan Joanne M. (CMO) reduced her position by 69.0% via a $685.3K sale on 2026-03-31 at $32.12 per share, executed near the stock's 52-week high of $31.94. This represents a significant portfolio reduction for a C-suite executive at a time when the company reported a full-year net income of $-40.7M, indicating ongoing unprofitability. The timing coincides with strong recent momentum (90-day change: +26.9%), though the current price of $31.50 sits only 1.4% below the 52-week high, suggesting the stock remains in elevated territory. Investors should note that the CMO's prior timing record at this ticker shows one measurable prior sell (on 2025-01-28) that was well-timed at the 90-day mark (90d return -43.2%), though the two most recent same-ticker sales (both on 2026-03-27) lack outcome data yet. The large reduction from 30.9K to 9.6K shares warrants attention to the company's operational trajectory and any forward-looking guidance, particularly given the unprofitable state and the executive's apparent confidence in this exit price.

CMO Donovan Joanne M. sold 16,358 shares for $506,734.85 at EWTX, reducing holdings 63.0%

Joanne M. Donovan, Chief Marketing Officer, executed 2 separate sales totaling 16,358 shares (16.4K shares) for $506,734.85 on 2026-03-27 at $30.98 per share, reducing her holdings from 25,955 shares to 9,597 shares, a reduction of 63.0% versus pre-transaction holdings. This represents a substantial liquidation of her position at a price near the 52-week high of $31.94. Her prior open-market sell (1 prior sell in TRACK RECORD) demonstrated a 90-day return of -43.2%, with a 90d well-timed rate of 100.00%, indicating her prior sells have historically been well-timed when the stock subsequently declined. The company reported a net loss of $-40,666,000.00 over its most recent full fiscal year, reflecting ongoing unprofitability, though the current market cap stands at $3,248,151,375.88. The magnitude of the position reduction and its execution at elevated valuation levels relative to recent range lows warrant observation of near-term price and fundamental developments.

CMO Donovan sells 25,000 EWTX shares at $27.63; retains 16,358 shares after 60.4% position reduction

Joanne M. Donovan, CMO of Edgewise Therapeutics, sold 25,000 shares at $27.63 on 2025-01-28, reducing her holdings by 60.4% to 16,358 shares. The sale occurred at a price 23.5% below the 52-week high of $36.62, within the company's $15.08–$36.62 annual range. The sale is notable in context of the company's negative financial performance: Edgewise reported net income of $-34,129,000 in its most recent full fiscal year. While the 90-day return of -17.6% followed this insider sale, the significance of this transaction reflects the magnitude of the position reduction and the company's unprofitable status, warranting investor attention to the CMO's conviction level and capital allocation priorities.